Relmada Therapeutics, Inc. Stock price

Equities

RLMD

US75955J4022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.59 USD -2.13% Intraday chart for Relmada Therapeutics, Inc. +3.49% +10.87%
Sales 2024 * - Sales 2025 * 3M Capitalization 138M
Net income 2024 * -112M Net income 2025 * -120M EV / Sales 2024 * -
Net cash position 2024 * 203M Net cash position 2025 * 124M EV / Sales 2025 * 4.89 x
P/E ratio 2024 *
-1.5 x
P/E ratio 2025 *
-1.95 x
Employees 20
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.76%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor MT
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer CI
Transcript : Relmada Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease MT
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023 CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board CI
Relmada Therapeutics Doses First Person in Phase 3 Trial of REL-1017 for Major Depressive Disorder MT
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder CI
Transcript : Relmada Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000 Index CI
More news

Latest transcript on Relmada Therapeutics, Inc.

1 day-2.13%
1 week+3.49%
Current month-25.06%
1 month-22.60%
3 months+8.77%
6 months+45.71%
Current year+10.87%
More quotes
1 week
4.40
Extreme 4.4
5.13
1 month
3.99
Extreme 3.99
7.22
Current year
2.92
Extreme 2.92
7.22
1 year
2.12
Extreme 2.1163
7.22
3 years
1.81
Extreme 1.81
40.00
5 years
1.81
Extreme 1.81
54.00
10 years
1.81
Extreme 1.81
80.00
More quotes
Managers TitleAgeSince
Founder 62 12-05-30
Chief Executive Officer 63 -
Director of Finance/CFO 59 15-11-11
Members of the board TitleAgeSince
Chairman 78 15-07-13
Chief Executive Officer 63 -
Director of Finance/CFO 59 15-11-11
More insiders
Date Price Change Volume
24-03-27 4.59 -2.13% 149,749
24-03-26 4.69 -4.29% 103,407
24-03-25 4.9 +0.82% 271,608
24-03-22 4.86 +4.29% 267,518
24-03-21 4.66 +5.07% 651,901

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company's lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company's lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive and monotherapy treatment of major depressive disorder.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
4.59 USD
Average target price
10.88 USD
Spread / Average Target
+136.93%
Consensus
  1. Stock
  2. Equities
  3. Stock Relmada Therapeutics, Inc. - Nasdaq